<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92480</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">N-Atsetiltsistein: bezopasnaya mnogogrannost'</article-title><trans-title-group xml:lang="ru"><trans-title>N-Ацетилцистеин: безопасная многогранность</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vizel'</surname><given-names>A. A</given-names></name><name xml:lang="ru"><surname>Визель</surname><given-names>А. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vizel'</surname><given-names>I. Yu</given-names></name><name xml:lang="ru"><surname>Визель</surname><given-names>И. Ю</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГОУ ВПО Казанский медицинский университет Росздрава</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2007-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2007</year></pub-date><volume>9</volume><issue>10</issue><issue-title xml:lang="en">VOL 9, NO10 (2007)</issue-title><issue-title xml:lang="ru">ТОМ 9, №10 (2007)</issue-title><fpage>21</fpage><lpage>25</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2007, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2007, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2007</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/92480">https://consilium.orscience.ru/2075-1753/article/view/92480</self-uri><abstract xml:lang="ru"><p>Современная фармакология богата препаратами, влияющими на кашель посредством различных механизмов — от блокады кашлевого рефлекса до стимуляции выработки слизи. В целом мукоактивные средства делят на несколько групп. Однако многие препараты обладают более широким спектром действия, и подчас их трудно отнести к какойлибо подгруппе по этому признаку. Многие мукоактивные лекарства обладают эффектом антиоксидантов. Разумно предположить, что их противовоспалительные свойства могут быть определяющими в их клинической эффективности. Японские исследователи именно с этой точки зрения в течение 20 лет проводили оценку эффекта нескольких мукоактивных препаратов. Было отмечено, что противовоспалительными свойствами обладали sodium aceneuramate, глюкокортикоиды, средства традиционной китайской медицины и новые производные цистеина [13]. В данной статье мы остановимся на хорошо известном, но до конца не изученном препарате – N-ацетилцистеине (N-АЦ). Его лекарственные формы разнообразны – растворимые таблетки и порошки, растворы для ингаляций, внутримышечного, внутривенного и эндобронхиального введения.N-АЦ является лекарственным средством, обладающим широким спектром действия при легочных заболеваниях (муколитик, антиоксидант). В токсикологической практике он применяется при отравлении парацетамолом, тяжелыми металлами, грибами. Анализ литературы показал, что клиническое изучение этого препарата далеко до завершения. Не исключено, что показания к его применению будут расширяться.</p></abstract></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Авдеев С.Н. Возможность уменьшения числа обострений у больных ХОБЛ при длительном приеме N-ацетилцистеина. Пульмонология. 2007; 2: 89–97.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Akerlund B, Tynell E, Bratt G et al. N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim - sulphamethoxazole in primary Pneumocystis carinii pro phylaxis in HIV-infected patients. J Infect 1997; 35 (2): 143–7.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Atkuri K.R, Mantovani J.J, Herzenberg L.A, Herzenberg L.A. N-Acetylcysteine - a safe anti dote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007; 7 (4)%: 355–9.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Decramer M, Rutten - van Molken M, Dekhuijzen P.N et al. Effects on N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo - controlled trial. Lancet 2005; 365 (9470): 1552–60.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Demedts M, Behr J, Buhl R et al. High - dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353 (21): 2229–42.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Flora S.J. Role of free radicals and antioxidants in health and disease. Cell Mol Biol (Noisy - le - grand). 2007; 53 (1): 1–2.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Gurbuz A.K, Ozel A.M, Ozturk R et al. Effect of N-acetyl cysteine on Helicobacter pylori. South Med J 2005; 98 (11): 1095–7.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hagiwara S.I, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med 2000; 162 (1): 225–31.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Jaworska M, Gillissen A, Scharling B et al. N-acetylcysteine: a functional oxygen radi cal scavenger in vitro and ex vivo in monocytes and neutrophilic granulocytes of patients with COPD. Pneumologie 1995; 49 (10): 539–45.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kasielski M, Nowak D. Long - term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001; 95 (6): 448–56.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kawase M, Sakagami H, Furuya K et al. Cell death - inducing activity of opiates in human oral tumor cell lines. Anticancer Res 2002; 22 (1A): 211–4.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kucukardali Y, Cinan U, Acar H.V et al. Comparison of the therapeutic efficacy of 4 methylpyrazole and N-acetylcysteine on acetaminophen (paracetamol) hepatotoxici ty in rats. Curr Med Res Opin 2002; 18 (2): 78–81.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Miyata T, Kai H, Isohama Y, Takahama K. Current opinion of muco - active drug research: strategies and problems. Eur Respir J 1998; 11: 480–91.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Rieutord A, Arnaud P, Dauphin J.F, Brion F. Stability and compatibility of an aerosol mixture including N - acetylcysteine, netilmicin and betamethasone. Int J Pharm 1999; 190 (1): 103–7.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Riise G.C, Larsson S, Larsson P et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy. Eur Respir J 1994; 7 (1): 94–101.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Rozanski G.J, Xu Z.Glutathione and K(+) channel remodeling in postinfarction rat heart. Am J Physiol Heart Circ Physiol 2002; 282 (6): 2346–55.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Stey C, Steurer J, Bachmann S et al. The effect of oral N-acetylcysteine in chronic bronchitis. a quantitative systemitic review. Eur Respir J 1999; 14 (Suppl. 30): Abstr. P2521.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Vecchiarelli A, Dottorini M, Pietrella D et al. Macrophage activation by N-acetylcys teine in COPD patients. Chest 1994; 105 (3): 806–11.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Walmsley S.L, Khorasheh S, Singer J, Djurdjev O. A randomized trial of N-acetylcys teine for prevention of trimethoprim - sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Net work 057 Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19 (5): 498–505.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Watanabe T, Pakala R, Katagiri T, Benedict C.R. Antioxidant N-acetylcysteine inhibits vasoactive agents - potentiated mitogenic effect of mildly oxidized LDL on vas cular smooth muscle cells. Hypertens Res 2002; 25 (2): 311–5.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zheng C.H, Ahmed K, Rikitomi N et al. The effects of S-carboxymethylcysteine and N acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithe lial cells. Microbiol Immunol 1999; 43 (2): 107–13.</mixed-citation></ref></ref-list></back></article>
